BridgeBio Pharma, Inc. (NASDAQ:BBIO) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT
Company Participants
Neil Kumar – Co-Founder, CEO & Director
Presentation
Unknown Analyst
Good afternoon. Welcome, everyone. My name is Jamie Adolph, and I’m an investment banker here at Morgan Stanley. Today, I’m joined by Neil Kumar, CEO and Founder of BridgeBio.
Thank you for joining us here today.
Neil Kumar
Co-Founder, CEO & Director
Thanks, Jamie. Thanks for having me and thanks to Jessica and the whole Morgan Stanley team for having me here again.
Unknown Analyst
Yes, of course. It’s great to have you back. Now before we kick off, I do have a few words on disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Question-and-Answer Session
Unknown Analyst
So that will kick things off. To start things off, can you give us a high-level overview of where BridgeBio stands today and how you see the company evolving from one approved product into a multistage multi-asset late-stage biotech?
Neil Kumar
Co-Founder, CEO & Director
Sure. Yes. Thanks for the question. So as I think many in the room know, this year has really been focused on the Attruby launch and proving that we can marry what I’ve seen is a high degree of R&D productivity with some commercial productivity and obviously, a lot more to do on that launch, but we’re happy with how that’s been evolving. And so where that really brings us right now is on the cusp of becoming, as you just mentioned, a multiproduct company with 3 Phase IIIs reading out here in the next 6 months in ADH1, in LGMD2I and in achondroplasia. And so the density of those readouts portends, I think, the making of the next really
#BridgeBio #Pharma #BBIO #Presents #Morgan #Stanley #23rd #Annual #Global #Healthcare